- Report
- October 2024
- 191 Pages
Global
From €3365EUR$3,545USD£2,839GBP
€3739EUR$3,939USD£3,154GBP
- Clinical Trials
- April 2024
- 60 Pages
Global
From €1899EUR$2,000USD£1,602GBP
- Report
- May 2024
- 128 Pages
Global
From €6170EUR$6,499USD£5,204GBP
- Drug Pipelines
- April 2024
- 60 Pages
Global
From €1899EUR$2,000USD£1,602GBP
- Report
- February 2023
- 120 Pages
Global
From €4272EUR$4,500USD£3,603GBP
- Report
- January 2022
- 200 Pages
Global
From €7120EUR$7,500USD£6,006GBP
- Report
- January 2022
- 60 Pages
Global
From €3750EUR$3,950USD£3,163GBP
- Report
- June 2023
- 180 Pages
Global
From €4698EUR$4,949USD£3,963GBP
- Report
- May 2022
- 80 Pages
Global
From €1899EUR$2,000USD£1,602GBP
The Lung Injury Drug market is a subset of the larger Respiratory Drugs market, which includes treatments for a variety of respiratory conditions such as asthma, COPD, and cystic fibrosis. Lung Injury Drugs are specifically designed to treat acute lung injury, a condition that can be caused by a variety of factors, including infection, trauma, and environmental toxins. These drugs are typically administered intravenously and can help reduce inflammation, improve oxygenation, and reduce the risk of further lung damage.
The Lung Injury Drug market is highly competitive, with a number of companies offering products that target different aspects of the condition. Some of the major players in the market include GlaxoSmithKline, AstraZeneca, Novartis, Merck, and Pfizer. Show Less Read more
